These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Design and synthesis of some β-carboline derivatives as multi-target anticancer agents.
    Author: Abdelsalam MA, AboulWafa OM, Badawey EA, El-Shoukrofy MS, El-Miligy MM, Gouda N.
    Journal: Future Med Chem; 2018 Dec; 10(24):2791-2814. PubMed ID: 30539666.
    Abstract:
    AIM: Some anticancer β-carbolines exhibited dual inhibition of topo-I and KSP. METHODOLOGY/RESULTS: Novel β-carbolines were synthesized and screened for their anticancer activity according to the NCI protocol. Five dose assays results indicated that compounds 9, 10, 12, 17 and 20 were potent and non selective anticancer agents; the sulfanyltriazole 12 was the most potent. Compounds 10, 12 and 20 showed dual topo-I and KSP inhibition with compound 12 being the most potent. Active compounds elicited Pre-G1 apoptosis and cell cycle arrest at G2/M phase of melanoma MDA-MB-435 cells. Docking results, in silico physicochemical and absorption, distribution, metabolism, excretion (ADME) properties were appropriate. CONCLUSION: Compounds 10, 12 and 20 are potent apoptosis-inducing multitarget anticancer agents that act via dual inhibition of topo-I and KSP-ATPase.
    [Abstract] [Full Text] [Related] [New Search]